For this study, 2 trained pulmonologists and 3 large-language models (ChatGPT 4o, DeepSeek R1, and Claude 3.5 Sonnet) assessed 100 random spirometry tests from children with varied underlying conditions, according to ERS/ATS 2019 guidelines. The large language models did not receive specific training, and all were tested using standardised prompts. Agreement with pulmonologists’ interpretations was assessed for test acceptability, clinical usability, and pulmonary function categorisation.
Dr Ece Ocak (İzmir City Hospital, Turkey) presented the results [1]. For pulmonary function testing, ChatGPT 4o achieved the highest agreement with the trained pulmonologists (Cohen’s kappa=0.515; moderate agreement), followed by DeepSeek R1 and Claude 3.5 Sonnet (both showing low agreement). However, “none of the large language models achieved substantial agreement for test acceptability or clinical usability,” said Dr Ocak. Furthermore, all models showed good accuracy for normal and obstructive spirometry patterns, but poor accuracy for restrictive and mixed patterns.
“Large language models may serve as a second reader to reduce variability,” concluded Dr Ocak. “Expanding training with larger and more diverse patient datasets could enhance diagnostic accuracy and support timely, standardised decision-making. Future research should address recognition of complex spirometry patterns and assess integration into real-world clinical workflows.”
- Ocak E, et al. Evaluation of artificial intelligence accuracy in interpreting pulmonary function tests: A comparison of ChatGPT 4o, DeepSeek R1, and Claude 3.5 Sonnet. ERS Congress, 27 September–1 October 2025, Amsterdam, the Netherlands.
Copyright ©2025 Medicom Publishing Group
Posted on
Previous Article
« Durvalumab in combination with chemotherapy shows promise for patients with SCLC and poor performance status Next Article
Morphine is not effective for chronic breathlessness and raises safety concerns »
« Durvalumab in combination with chemotherapy shows promise for patients with SCLC and poor performance status Next Article
Morphine is not effective for chronic breathlessness and raises safety concerns »
Table of Contents: ERS 2025
Featured articles
Early data suggest a potential benefit of taladegib in idiopathic pulmonary fibrosis
Astegolimab shows promise as a potential treatment for chronic obstructive pulmonary disease
Pulmonary Hypertension
TPIP-202 results confirm the efficacy of treprostinil palmitil inhalation powder in pulmonary arterial hypertension
Sotatercept is becoming a treatment option for patients with newly diagnosed pulmonary arterial hypertension
Lung Cancer and Other Clinical Insights
Does paracetamol cause eczema or bronchiolitis in infants?
Morphine is not effective for chronic breathlessness and raises safety concerns
How accurate are large language models for spirometry interpretation?
Durvalumab in combination with chemotherapy shows promise for patients with SCLC and poor performance status
Obstructive Airway Diseases
Dupilumab is superior to omalizumab in adults with chronic rhinosinusitis with nasal polyps and asthma
Budesonide/glycopyrronium/formoterol fumarate dihydrate for inadequately controlled asthma
Budesonide-formoterol reliever outperforms salbutamol in children with mild asthma
Astegolimab shows promise as a potential treatment for chronic obstructive pulmonary disease
Mepolizumab preserves lung function for up to 2 years in eosinophilic COPD
Respiratory Infections and Inflammation
Are patients with pulmonary sarcoidosis overtreated with corticosteroids?
Are mucoactive agents helpful in patients with bronchiectasis?
Brensocatib is efficacious in patients with bronchiectasis and more than 2 annual exacerbations
Inhaled heparin improves outcomes in non-intubated COVID-19 patients
Can children with infectious conditions requiring oxygen therapy be discharged at a SpO2 of 88%?
Beta-lactam antibiotics plus doxycycline are an alternative to azithromycin in severe community-acquired pneumonia
Interstitial and Fibrotic Lung Diseases
Updated results from FIBRONEER-IPF confirm nerandomilast efficacy over 76 weeks
Early data suggest a potential benefit of taladegib in idiopathic pulmonary fibrosis
TETON-2 highlights inhaled treprostinil as a treatment option for idiopathic pulmonary fibrosis
Related Articles
September 13, 2017
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
